Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives - Wikidata - wikimedia - TriplyDB

Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives

Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives

http://www.wikidata.org/entity/Q26741152

about

Future drug discovery in renin-angiotensin-aldosterone system intervention.New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations.Awareness of physicians and pharmacists of aldosterone antagonists in heart failure and myocardial infarction in Jordan European Heart Journal-Cardiovascular Pharmacotherapy in 2016: entering a new level of international recognition.2017 EACTS Guidelines on perioperative medication in adult cardiac surgery.Aldosterone a Relevant Factor in the Beginning and Evolution of Arterial Hypertension.The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.

P2860

Q38679303-E01A41EA-BD49-4092-A22D-2119211E9C5A Q39218629-92B7BB2A-184C-4D70-A5CD-E67063F2CBBF Q41702156-D1A23010-3572-48C6-83DE-87F819D114F1 Q48714148-4EC7901A-01D2-4FA2-8E64-520CC81D5683 Q50065204-53FFC40B-A34A-4ACA-9665-2942A2125228 Q50212546-2FF8D6FF-C427-4623-9468-686624D531A5 Q52580660-8AF05164-9175-48FF-A07A-32BB895B1B27

P2860

Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives

http://www.wikidata.org/entity/Q26741152

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Mineralocorticoid receptor ant ...... rience and future perspectives

@ast

Mineralocorticoid receptor ant ...... rience and future perspectives

@en

Mineralocorticoid receptor ant ...... rience and future perspectives

@nl

type

label

Mineralocorticoid receptor ant ...... rience and future perspectives

@ast

Mineralocorticoid receptor ant ...... rience and future perspectives

@en

Mineralocorticoid receptor ant ...... rience and future perspectives

@nl

prefLabel

Mineralocorticoid receptor ant ...... rience and future perspectives

@ast

Mineralocorticoid receptor ant ...... rience and future perspectives

@en

Mineralocorticoid receptor ant ...... rience and future perspectives

@nl

P1433

Q26741152-A8CC7A7E-D7DD-46C6-BD25-0799DF06F584

P1476

Q26741152-D7C98AB1-3E6E-442B-9611-BB2BB5BBFC60

P2093

Q26741152-996C9A78-F0AF-41FC-8FD7-A3627FD625B4

P2860

Q26741152-0018104C-94C0-46D2-A45A-2076CD4CDD61

Q26741152-00493C7B-9B1E-4F3E-BE90-51BD4F3D8190

Q26741152-03112808-E2A7-4C65-8C8C-CBB7B7D3EE85

Q26741152-04988343-8036-411D-A20D-53879F8EC48B

Q26741152-053B797E-3ADF-4BF2-B665-1EF66DE4AE47

Q26741152-0C32EFF9-999D-4057-B212-26707FB8EB78

Q26741152-106B0160-7913-4FC3-B388-FA5755DD3F55

Q26741152-11F06BEA-3112-4759-B6E9-4630EBE5C54A

Q26741152-1F6A1998-718C-4C1E-92C9-33F5C567F8E3

Q26741152-2273E2F0-B7CA-4883-B37A-9E5A00A3288C

P31

Q26741152-F2A4F734-67BA-4A1A-9E95-5BD879AB8880

P356

Q26741152-ACAF5A9C-A545-4C74-BB6B-C8352864D08A

P50

Q26741152-53B6730A-4E28-48A6-9B91-FB041EF512EA

Q26741152-EDFC581C-58AB-4C04-887B-5FDD53E30258

P577

Q26741152-0D20E35C-AC21-4506-9865-B193BE2846EF

P698

Q26741152-5383A317-CECE-443F-B391-21C453EC9916

P921

Q26741152-8E45DBA8-23AE-49C6-8C13-40AC130B125B

Q26741152-9E545933-627E-4284-B8F0-46AA36706F27

P356

P1433

European heart journal. Cardiovascular pharmacotherapy

P1476

Mineralocorticoid receptor ant ...... rience and future perspectives

@en

P2093

João Pedro Ferreira

http://www.w3.org/2001/XMLSchema#string

P2860

Geographic differences in heart failure trials

Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study

A comparison of the aldosterone-blocking agents eplerenone and spironolactone

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.

The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.

Spironolactone for heart failure with preserved ejection fraction.

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

Nonsteroidal antagonists of the mineralocorticoid receptor.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut

P31

scholarly article

P356

10.1093/EHJCVP/PVW016

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27530337

http://www.w3.org/2001/XMLSchema#string

P921

mineralocorticoid